Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
peer reviewed ; [en] OBJECTIVES: Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real-world setting in Belgium. METHODS: This was a retrospective, multicentre cohort study involving adult treatment-naïve (TN) and treatment-experienced (TE) people living with HIV receiving BIC/FTC/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV-1 viral load <50 copies/mL; on-treatment analysis) at weeks 24 and 48. The main secondary outcomes incl... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2023 |
Verlag/Hrsg.: |
John Wiley and Sons Inc
|
Schlagwörter: | HIV / bictegravir/emtricitabine/tenofovir alafenamide / efficacy / real-world data / tolerability / Health Policy / Infectious Diseases / Pharmacology (medical) / Human health sciences / Immunology & infectious disease / Sciences de la santé humaine / Immunologie & maladie infectieuse |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26593272 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/304048 |